Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

M0CRPC overview of management options.

Hess-Busch Y, Hadaschik B, Hess J.

World J Urol. 2019 Nov 5. doi: 10.1007/s00345-019-02997-z. [Epub ahead of print] Review.

PMID:
31691081
2.

Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies.

Alpajaro SIR, Harris JAK, Evans CP.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):16-23. doi: 10.1038/s41391-018-0078-1. Epub 2018 Aug 16. Review.

PMID:
30115959
3.

Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.

Chowdhury S, Oudard S, Uemura H, Joniau S, Pilon D, Ladouceur M, Behl AS, Liu J, Dearden L, Sermon J, Van Sanden S, Diels J, Hadaschik BA.

Adv Ther. 2020 Jan;37(1):501-511. doi: 10.1007/s12325-019-01156-5. Epub 2019 Dec 7.

PMID:
31813086
4.

Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction.

Esther J, Maughan BL, Anderson N, Agarwal N, Hahn AW.

Curr Treat Options Oncol. 2019 Feb 11;20(2):14. doi: 10.1007/s11864-019-0611-z. Review.

PMID:
30741354
5.

Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.

Fizazi K, Smith MR, Tombal B.

Clin Genitourin Cancer. 2018 Oct;16(5):332-340. doi: 10.1016/j.clgc.2018.07.017. Epub 2018 Jul 24. Review.

6.

Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide.

Gul A, Garcia JA, Barata PC.

Cancer Manag Res. 2019 Aug 1;11:7253-7262. doi: 10.2147/CMAR.S165706. eCollection 2019.

7.

Darolutamide For Castration-Resistant Prostate Cancer.

Bastos DA, Antonarakis ES.

Onco Targets Ther. 2019 Oct 23;12:8769-8777. doi: 10.2147/OTT.S197244. eCollection 2019.

8.

Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.

Saad F, Cella D, Basch E, Hadaschik BA, Mainwaring PN, Oudard S, Graff JN, McQuarrie K, Li S, Hudgens S, Lawson J, Lopez-Gitlitz A, Yu MK, Smith MR, Small EJ.

Lancet Oncol. 2018 Oct;19(10):1404-1416. doi: 10.1016/S1470-2045(18)30456-X. Epub 2018 Sep 10.

PMID:
30213449
9.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
10.

Managing Nonmetastatic Castration-resistant Prostate Cancer.

Mateo J, Fizazi K, Gillessen S, Heidenreich A, Perez-Lopez R, Oyen WJG, Shore N, Smith M, Sweeney C, Tombal B, Tomlins SA, de Bono JS.

Eur Urol. 2019 Feb;75(2):285-293. doi: 10.1016/j.eururo.2018.07.035. Epub 2018 Aug 14. Review.

11.

Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer.

Chowdhury S, Oudard S, Uemura H, Joniau S, Pilon D, Lefebvre P, McQuarrie K, Liu J, Dearden L, Sermon J, Van Sanden S, Diels J, Hadaschik BA.

Adv Ther. 2020 Jan;37(1):512-526. doi: 10.1007/s12325-019-01157-4. Epub 2019 Dec 7.

PMID:
31813087
12.

Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials.

Koshkin VS, Small EJ.

Ther Adv Urol. 2018 Nov 11;10(12):445-454. doi: 10.1177/1756287218811450. eCollection 2018 Dec. Review.

13.

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.

Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G, Alumkal JJ, Higano CS, Chow Maneval E, Bandekar R, de Boer CJ, Yu MK, Rathkopf DE.

Eur Urol. 2016 Dec;70(6):963-970. doi: 10.1016/j.eururo.2016.04.023. Epub 2016 May 6.

14.

[Influence of modern diagnostic methods on the treatment of nonmetastatic castration-resistant prostate cancer].

Kretschmer A, Tilki D.

Urologe A. 2019 May;58(5):529-534. doi: 10.1007/s00120-019-0904-7. Review. German.

PMID:
30887058
15.

Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date.

Chong JT, Oh WK, Liaw BC.

Onco Targets Ther. 2018 Apr 12;11:2141-2147. doi: 10.2147/OTT.S147168. eCollection 2018. Review.

16.

Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide.

Wallis CJD, Chandrasekar T, Goldberg H, Klotz L, Fleshner N, Satkunasivam R, Klaassen Z.

Eur Urol Oncol. 2018 Aug;1(3):238-241. doi: 10.1016/j.euo.2018.04.004. Epub 2018 May 15.

PMID:
31102627
17.

Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.

Al-Salama ZT.

Drugs. 2019 Sep;79(14):1591-1598. doi: 10.1007/s40265-019-01194-x. Review.

PMID:
31489589
18.

Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer.

Mori K, Kimura T, Fukuokaya W, Iwatani K, Sakanaka K, Kurokawa G, Yanagisawa T, Sasaki H, Miki J, Shimomura T, Miki K, Hatano T, Endo K, Egawa S.

Int J Clin Oncol. 2019 Sep 11. doi: 10.1007/s10147-019-01541-8. [Epub ahead of print]

PMID:
31512007
19.

Darolutamide (ODM-201) for the treatment of prostate cancer.

Shore ND.

Expert Opin Pharmacother. 2017 Jun;18(9):945-952. doi: 10.1080/14656566.2017.1329820. Epub 2017 May 24. Review.

PMID:
28490267
20.

Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial.

Shore N, Zurth C, Fricke R, Gieschen H, Graudenz K, Koskinen M, Ploeger B, Moss J, Prien O, Borghesi G, Petrenciuc O, Tammela TL, Kuss I, Verholen F, Smith MR, Fizazi K.

Target Oncol. 2019 Oct;14(5):527-539. doi: 10.1007/s11523-019-00674-0.

Supplemental Content

Support Center